<DOC>
	<DOC>NCT01420055</DOC>
	<brief_summary>This is a prospective, open-label, multi-center phase IV study to assess response to fingolimod initiation according to coping profile in adult patients with highly active relapsing remitting multiple sclerosis in France.</brief_summary>
	<brief_title>Fingolimod -Response According to Coping - Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>1865 yearold male &amp; female with RRMS (2005 revised McDonald criteria) corresponding to fingolimod indication (in Europe) and EDSS score 0 5.5 inclusive History of immune system chronic disease other than MS or known immunodeficiency syndrome; increased risk for opportunistic infections, including immunocompromised patients; severe active infections, active chronic infections; negative for varicellazoster virus IgG antibodies; live or live attenuated vaccines; Active malignancies; Macular edema; Cardiac disease or medicines decreasing heart rate; severe liver impairment; lymphocyte count &lt;800/mm3; Pregnant or nursing (lactating) women /childbearing potential UNLESS they are using an effective contraceptive method; Hypersensitivity; participation in any clinical research study within 6 months prior to baseline; prior participation in a trial with fingolimod Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Coping</keyword>
	<keyword>Anxiety</keyword>
	<keyword>France</keyword>
	<keyword>Treatment Satisfaction Questionnaire for Medication-9 items (TSQM 9)</keyword>
	<keyword>Active</keyword>
</DOC>